Vincerx Pharma, Inc. (VINC)
US — Healthcare Sector
Automate Your Wheel Strategy on VINC
With Tiblio's Option Bot, you can configure your own wheel strategy including VINC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VINC
- Rev/Share 0.0
- Book/Share 0.5771
- PB 0.0953
- Debt/Equity 0.0
- CurrentRatio 1.7885
- ROIC -13.0942
- MktCap 287885.0
- FreeCF/Share -6.3804
- PFCF -0.0126
- PE -0.0087
- Debt/Assets 0.0
- DivYield 0
- ROE -3.0866
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Vincerx Pharma, Inc. (VINC)
- IPO Date 2020-05-27
- Website https://vincerx.com
- Industry Biotechnology
- CEO Dr. Raquel E. Izumi Ph.D.
- Employees 12
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.